Abbott Laboratories raised its 2018 full-year earnings forecast and reported a quarterly profit that beat analysts’ estimates, powered by higher sales across its businesses.
J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.
U.S. regulators said Mylan NV’s EpiPen products are in shortage, due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.
Novartis’ first quarterly results under new CEO Vas Narasimhan were marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by the company’s U.S. generics unit.
Johnson & Johnson reported a strong first-quarter 2018 with $20 billion in sales that was fueled by significant growth in the company’s pharmaceuticals business.
Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.
In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.
AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.
As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.
Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.
Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.
Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.
Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.
Sanofi expected 2017 EPS to be stable or slightly lower after its fourth-quarter 2016 results were affected by an increase in taxes and one-off charges.
Merck & Co. Inc. reported better-than-expected U.S. quarterly sales for its key cancer drug Keytruda and forecast largely in-line 2017 results.
Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.
Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.
While there were definitely positive items in Biogen’s third-quarter 2016 report, the company also threw in what almost seemed like an afterthought – it was no longer developing amiselimod (MT-1303).
Abbott Laboratories reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.
Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.